Taysha Gene Therapies, Inc. (TSHA) Research

Taysha Gene Therapies, Inc. is a biotech firm specializing in the creation and market introduction of gene therapies that utilize adeno-associated virus (AAV) vectors. Its core mission is to tackle inherited diseases affecting the central nervous system (CNS). The company's development pipeline features several key programs: TSHA-120 is aimed at giant axonal neuropathy; TSHA-102 is in development for Rett syndrome; TSHA-121 and TSHA-118 are both being advanced for CLN1 disease; TSHA-105 addresses SLC13A5 Deficiency; and TSHA-101 targets GM2 gangliosidosis. Furthermore, Taysha has forged a strategic alliance with The University of Texas Southwestern Medical Center to jointly advance and bring to market innovative gene therapy solutions. Founded in 2019, the company operates from its headquarters in Dallas, Texas.

Market snapshot

Symbol
TSHA
Price
$6.42
Day change
+3.72%
Market cap
$1.6B
P/E ratio
-16.77x
52-week range
2.25-7.3
Sector
Healthcare
Industry
Biotechnology
Next earnings
in 2 months
Analyst price target
$12.00

Peer companies

  • AnaptysBio, Inc. (ANAB)
  • Atai Beckley Inc. (ATAI)
  • BridgeBio Oncology Therapeutics Inc. (BBOT)
  • Dianthus Therapeutics, Inc. (DNTH)
  • Enliven Therapeutics, Inc. (ELVN)
  • Immatics N.V. (IMTX)
  • Nektar Therapeutics (NKTR)
  • Oculis Holding AG (OCS)

Recent insider activity

  • Stalfort John A III — A-Award (21335 shares) on 2026-06-01
  • Stalfort John A III — A-Award (42671 shares) on 2026-06-01
  • Donenberg Phillip B. — A-Award (21335 shares) on 2026-06-01
  • Donenberg Phillip B. — A-Award (42671 shares) on 2026-06-01
  • Long Alison S — A-Award (21335 shares) on 2026-06-01

Open Taysha Gene Therapies, Inc. (TSHA) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.